Hancock Whitney Corp Sells 10,362 Shares of Edwards Lifesciences Co. (NYSE:EW)

Hancock Whitney Corp reduced its stake in Edwards Lifesciences Co. (NYSE:EW) by 33.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 20,379 shares of the medical research company’s stock after selling 10,362 shares during the period. Hancock Whitney Corp’s holdings in Edwards Lifesciences were worth $1,509,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Crowley Wealth Management Inc. purchased a new position in Edwards Lifesciences during the 4th quarter valued at approximately $26,000. Millstone Evans Group LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences in the fourth quarter worth $30,000. Roble Belko & Company Inc purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $76.06 on Friday. The firm has a market cap of $44.71 billion, a price-to-earnings ratio of 10.91, a PEG ratio of 4.82 and a beta of 1.15. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $95.25. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The company’s 50 day moving average is $70.94 and its 200 day moving average is $71.07.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, topping the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. During the same period in the previous year, the company posted $0.66 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven R. Loranger sold 5,739 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,853 shares of company stock worth $5,163,062. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of several recent research reports. Barclays upped their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Canaccord Genuity Group raised their price objective on Edwards Lifesciences from $71.00 to $75.00 and gave the company a “hold” rating in a research note on Friday. Truist Financial cut their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Finally, Piper Sandler upgraded shares of Edwards Lifesciences from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $73.00 to $80.00 in a research report on Thursday. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and an average price target of $79.45.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.